Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Press releases

January 19, 2016 | REGULATORY

Immunovia and the University of Liverpool enter into a collaboration in a prospective clinical study

Read press release
December 18, 2015 | REGULATORY

White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

Read press release
December 3, 2015 | REGULATORY

IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples

Read press release
December 2, 2015 | REGULATORY

Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Read press release
November 26, 2015

Immunovia approved for trading on Nasdaq First North as of December 1st, 2015

Read press release
October 5, 2015

Immunovia, OHSU collaborating on early detection test for pancreatic cancer

Read press release
1 25 26 27